Trial Profile
The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Ceralasertib (Primary) ; Fulvestrant (Primary) ; Neratinib (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms plasmaMATCH
- 09 Dec 2023 Results (n=75) assessing paired baseline and early on treatment ctDNA analysis from cohort E of this trial were presented at the 46th Annual San Antonio Breast Cancer Symposium
- 07 Jun 2022 Results (n=84) assessing analysis of baseline and end-of-treatment (EOT) ctDNA to identify potential resistance mutations to fulvestrant presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results (n=75) assessing safety and efficacy from cohort E of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology